Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 01/18 03:47:03 am
84.63 CHF   -0.79%
01/17NOVARTIS : to Continue Global Gene Therapy Access Program in 2021
MT
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
01/15NOVARTIS AG : Gets a Buy rating from Deutsche Bank
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : to Repurchase Up to $2.5 Billion in Shares

11/24/2020 | 01:47am EST

By Cecilia Butini

Novartis AG said Tuesday it is initiating a share-buyback program of up to $2.5 billion that will start immediately and last into the first half of 2021.

The Swiss pharmaceutical major also said it will deliver $2 billion in cost savings by the end of the year through its Novartis Technical Operations and Novartis Business Services units.

Novartis's Technical Operations unit has productivity programs in place that are set to generate a further $2 billion in mid-term cost reductions, the company said.

The company said that it expects its pipeline to fuel growth in the mid- to long term, and that it expects key milestones from mid- to late-stage assets from its pharmaceutical business to come through in 2021 and 2022.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

11-24-20 0146ET

All news about NOVARTIS AG
01/17NOVARTIS : to Continue Global Gene Therapy Access Program in 2021
MT
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
01/15NOVARTIS AG : Gets a Buy rating from Deutsche Bank
MD
01/15NOVARTIS : Exane BNP Paribas Lowers Price Target on Novartis, Maintains Outperfo..
MT
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
MT
01/14NOVARTIS : Gets FDA Breakthrough-Therapy Designation for Ligelizumab
DJ
01/14NOVARTIS AG : UBS maintains a Buy rating
MD
01/14NOVARTIS' : Ligelizumab Receives FDA Breakthrough Therapy Designation for Urtica..
MT
01/14NOVARTIS : Skin Disease Treatment Ligelizumab Gets US FDA's Breakthrough Therapy..
MT
01/14NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language
AQ
More news
Financials (USD)
Sales 2020 49 176 M - -
Net income 2020 8 396 M - -
Net Debt 2020 19 973 M - -
P/E ratio 2020 26,0x
Yield 2020 3,31%
Capitalization 218 B 218 B -
EV / Sales 2020 4,83x
EV / Sales 2021 4,42x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,22 $
Last Close Price 95,66 $
Spread / Highest target 47,2%
Spread / Average Target 14,2%
Spread / Lowest Target -14,1%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG1.97%218 041
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120